First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer☆
Titel:
First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer☆
Auteur:
Niu, J. Maurice-Dror, C. Lee, D.H. Kim, D.-W. Nagrial, A. Voskoboynik, M. Chung, H.C. Mileham, K. Vaishampayan, U. Rasco, D. Golan, T. Bauer, T.M. Jimeno, A. Chung, V. Chartash, E. Lala, M. Chen, Q. Healy, J.A. Ahn, M.-J.
Verschenen in:
Annals of oncology
Paginering:
Jaargang 33 () nr. 2 pagina's 169-180
Jaar:
2022
Inhoud:
Uitgever:
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, The Author(s)